These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 9631086)

  • 1. Engineering antibody Fv fragments for cancer detection and therapy: disulfide-stabilized Fv fragments.
    Reiter Y; Brinkmann U; Lee B; Pastan I
    Nat Biotechnol; 1996 Oct; 14(10):1239-45. PubMed ID: 9631086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody engineering of recombinant Fv immunotoxins for improved targeting of cancer: disulfide-stabilized Fv immunotoxins.
    Reiter Y; Pastan I
    Clin Cancer Res; 1996 Feb; 2(2):245-52. PubMed ID: 9816166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineering interchain disulfide bonds into conserved framework regions of Fv fragments: improved biochemical characteristics of recombinant immunotoxins containing disulfide-stabilized Fv.
    Reiter Y; Brinkmann U; Webber KO; Jung SH; Lee B; Pastan I
    Protein Eng; 1994 May; 7(5):697-704. PubMed ID: 8073039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activity and pharmacokinetics in mice of a recombinant immunotoxin containing a disulfide-stabilized Fv fragment.
    Reiter Y; Pai LH; Brinkmann U; Wang QC; Pastan I
    Cancer Res; 1994 May; 54(10):2714-8. PubMed ID: 8168102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disulfide stabilization of antibody Fv: computer predictions and experimental evaluation.
    Reiter Y; Brinkmann U; Jung SH; Pastan I; Lee B
    Protein Eng; 1995 Dec; 8(12):1323-31. PubMed ID: 8869646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved stability and yield of Fv targeted superantigen by introducing both linker and disulfide bond into the targeting moiety.
    Hao HJ; Jiang YQ; Zheng YL; Ma R; Yu DW
    Biochimie; 2005 Aug; 87(8):661-7. PubMed ID: 15927340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions.
    Reiter Y; Brinkmann U; Kreitman RJ; Jung SH; Lee B; Pastan I
    Biochemistry; 1994 May; 33(18):5451-9. PubMed ID: 7910034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crystal structure of the disulfide-stabilized Fv fragment of anticancer antibody B1: conformational influence of an engineered disulfide bond.
    Almog O; Benhar I; Vasmatzis G; Tordova M; Lee B; Pastan I; Gilliland GL
    Proteins; 1998 May; 31(2):128-38. PubMed ID: 9593187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Construction of a functional disulfide-stabilized TCR Fv indicates that antibody and TCR Fv frameworks are very similar in structure.
    Reiter Y; Kurucz I; Brinkmann U; Jung SH; Lee B; Segal DM; Pastan I
    Immunity; 1995 Mar; 2(3):281-7. PubMed ID: 7697545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phage display of disulfide-stabilized Fv fragments.
    Brinkmann U; Chowdhury PS; Roscoe DM; Pastan I
    J Immunol Methods; 1995 May; 182(1):41-50. PubMed ID: 7769243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytotoxic and antitumor activity of a recombinant immunotoxin composed of disulfide-stabilized anti-Tac Fv fragment and truncated Pseudomonas exotoxin.
    Reiter Y; Kreitman RJ; Brinkmann U; Pastan I
    Int J Cancer; 1994 Jul; 58(1):142-9. PubMed ID: 8014011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant single-chain and disulfide-stabilized Fv immunotoxins for cancer therapy.
    Niv R; Segal D; Reiter Y
    Methods Mol Biol; 2003; 207():255-68. PubMed ID: 12412479
    [No Abstract]   [Full Text] [Related]  

  • 13. Development of a humanized disulfide-stabilized anti-p185HER2 Fv-beta-lactamase fusion protein for activation of a cephalosporin doxorubicin prodrug.
    Rodrigues ML; Presta LG; Kotts CE; Wirth C; Mordenti J; Osaka G; Wong WL; Nuijens A; Blackburn B; Carter P
    Cancer Res; 1995 Jan; 55(1):63-70. PubMed ID: 7805042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A form of anti-Tac(Fv) which is both single-chain and disulfide stabilized: comparison with its single-chain and disulfide-stabilized homologs.
    Rajagopal V; Pastan I; Kreitman RJ
    Protein Eng; 1997 Dec; 10(12):1453-9. PubMed ID: 9543007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A recombinant immunotoxin containing a disulfide-stabilized Fv fragment.
    Brinkmann U; Reiter Y; Jung SH; Lee B; Pastan I
    Proc Natl Acad Sci U S A; 1993 Aug; 90(16):7538-42. PubMed ID: 8356052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutual stabilization of VL and VH in single-chain antibody fragments, investigated with mutants engineered for stability.
    Wörn A; Plückthun A
    Biochemistry; 1998 Sep; 37(38):13120-7. PubMed ID: 9748318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved stability and yield of a Fv-toxin fusion protein by computer design and protein engineering of the Fv.
    Chowdhury PS; Vasmatzis G; Beers R; Lee B; Pastan I
    J Mol Biol; 1998 Sep; 281(5):917-28. PubMed ID: 9719644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A bivalent disulfide-stabilized Fv with improved antigen binding to erbB2.
    Bera TK; Onda M; Brinkmann U; Pastan I
    J Mol Biol; 1998 Aug; 281(3):475-83. PubMed ID: 9698563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid and specific uptake of anti-Tac disulfide-stabilized Fv by interleukin-2 receptor-bearing tumors.
    Webber KO; Kreitman RJ; Pastan I
    Cancer Res; 1995 Jan; 55(2):318-23. PubMed ID: 7812965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved binding and antitumor activity of a recombinant anti-erbB2 immunotoxin by disulfide stabilization of the Fv fragment.
    Reiter Y; Brinkmann U; Jung SH; Lee B; Kasprzyk PG; King CR; Pastan I
    J Biol Chem; 1994 Jul; 269(28):18327-31. PubMed ID: 7913461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.